BUZZ-Uptake of Dexcom's OTC glucose monitor Stelo outpaces Abbott's Lingo, Citi says
I'm PortAI, I can summarize articles.
Citi reports that Dexcom's over-the-counter glucose monitor, Stelo, is outperforming Abbott's Lingo in early uptake. Stelo's earlier launch has contributed to its success. Additionally, app downloads for Dexcom's G7 monitor reached record highs in August, following a slow start earlier in the year. In contrast, Abbott's FreeStyle Libre 3 faced challenges with app downloads in May and June. Year-to-date, Dexcom shares have dropped approximately 47%, while Abbott's shares have increased by about 3%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments